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Lorena Fariñas‑Madrid2, Victor Rodriguez‑Freixinos4, Pedro Mallol5, Raquel Lopez‑Reig6,7 & 
Jose Antonio Lopez‑Guerrero6,7,8
The poly (ADP‑Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients 
with ovarian or breast cancer with or without BRCA1/2 mutations. Lurbinectedin is an ecteinascidin 
that generates DNA double‑strand breaks. We hypothesized that the combination of olaparib and 
lurbinectedin maximizes the DNA damage increasing the efficacy. A 3 + 3 dose‑escalation study 
examined olaparib tablets with lurbinectedin every 21 days. The purpose of this phase I study is 
to determine the dose‑limiting toxicities (DLTs) of the combination, to investigate the maximum 
tolerated dose (MTD), the recommended phase II dose (RP2D), efficacy, pharmacokinetics, in addition 
to genotyping and translational studies. In total, 20 patients with ovarian and endometrial cancers 
were included. The most common adverse events were asthenia, nausea, vomiting, constipation, 
abdominal pain, neutropenia, anemia. DLT grade 4 neutropenia was observed in two patients in 
dose level (DL) 5, DL4 was defined as the MTD, and the RP2D was lurbinectedin 1.5 mg/m2 + olaparib 
250 mg twice a day (BID). Mutational analysis revealed a median of 2 mutations/case, 53% of patients 
with mutations in the homologous recombination (HR) pathway. None of the patients reached a 
complete or partial response; however, 60% of stable disease was achieved. In conclusion, olaparib in 
combination with lurbinectedin was well tolerated with a disease control rate of 60%. These results 
deserve further evaluation of the combination in a phase II trial.
Olaparib is a potent oral poly (ADP-Ribose) polymerase (PARP) inhibitor that leads to synthetic lethality in 
patients with BRCA1/2 deficient tumor  cells1. Moreover, increasing data suggest that PARP inhibitors may have 
a role in the treatment of sporadic high-grade serous ovarian and other cancers with homologous recombination 
deficiency (HRD)2. Continuous oral olaparib showed efficacy in heavily pretreated mutated BCRA1/2 breast 
 cancer3–5. Olaparib as monotherapy improved progression-free survival (PFS) in patients with platinum-sensitive 
relapsed serous ovarian cancers regardless of BRCA  status6–9, and in BRCA mutated patients with ovarian and 
breast cancers previously treated with  chemotherapy10.
In addition to the single-agent studies, olaparib has been combined with chemotherapy since it might act 
as sensitizer by limiting DNA damage  repair11. Phase I and II clinical trials assessing olaparib combined with 
standard chemotherapy have shown encouraging results in ovarian and breast  cancers12–16.
OPEN
1Oncogynecologic Department, Initia Oncology, Hospital Quironsalud Valencia, Avda Blasco Ibañez, 14, 46 
010 Valencia, Spain. 2Medical Oncology Department, Vall D’Hebron University Hospital, Vall D’Hebron Institute 
of Oncology (VHIO), Barcelona, Spain. 3Department of Medical Oncology, Fundación Instituto Valenciano de 
Oncología (IVO), Valencia, Spain. 4Department of Medical Oncology and Hematology, Odette Cancer Centre, 
Sunnybrook Health Sciences Centre, Toronto, Canada. 5Clinical Trials Department, FINCIVO (Fundación de 
Investigación Clínica del IVO), Valencia, Spain. 6Laboratory of Molecular Biology, Fundación Instituto Valenciano 
de Oncología, Valencia, Spain. 7IVO-CIPF Joint Research Unit of Cancer, Príncipe Felipe Research Center (CIPF), 
Valencia, Spain. 8Department of Pathology, School of Medicine, Catholic University of Valencia ‘San Vicente 
Martir’, Valencia, Spain. *email: apoveda@initiaoncologia.com
2
Vol:.(1234567890)
Scientific Reports |         (2021) 11:4433  | https://doi.org/10.1038/s41598-021-82671-w
www.nature.com/scientificreports/
Lurbinectedin (PM01183) is a new synthetic alkaloid, structurally related to ecteinascidins. In common with 
trabectedin, lurbinectedin contains a pentacyclic skeleton composed of two fused tetrahydroisoquinoline rings 
(subunits A and B) that is mostly responsible for DNA recognition and binding. The additional module (ring 
C) in lurbinectedin is a tetrahydro β-carboline rather than the additional tetrahydroisoquinoline present in 
trabectedin. This structural difference may confer pharmacokinetic benefits as well as intrinsic  activity17. Lur-
binectedin inhibits the transcription process through its binding to CG-rich sequences, induces the generation 
of double-strand DNA breaks and subsequent  apoptosis18 and also reduces tumor-associated macrophages and 
the inflammatory microenvironment through the inhibition of inflammatory  factors19. Since these DNA double-
stand breaks are processed through homologous recombinant repair (HRR), trabectedin and lurbinectedin are 
particularly associated with sensitivity in HRR-deficient  cells20. A recent study reported an impressive activity 
in platinum-resistant ovarian cancer patients in terms of ORR, PFS and  OS21.
The combination of olaparib, an inhibitor of DNA damage repair (DDR), with a DNA damaging agent such 
as lurbinectedin seems an interesting approach to maximize the effect of DNA damage. In preclinical models, the 
combination of both agents was synergistic and led to biologically significant deregulation of the DDR machinery 
that elicited relevant antitumor  activity22. However, the major concern over the combinations is overlapping 
toxicities. Single-agent lurbinectedin showed significant hematological toxicity with grade 3–4 neutropenia up 
to 85% when administered at flat  dose21, being lower (57%) when the dose is adjusted to body surface  area23. 
Moreover, treatment with chemotherapy and continuous dosing of olaparib is usually not feasible due to the high 
rate of hematologic adverse events. An intermittent schedule of olaparib is better tolerated than a continuous 
one when combined with  chemotherapy14,24.
This phase I dose-escalation trial was designed to determine the safety and the recommended dose of lurbi-
nectedin combined with a short course of olaparib administered every three weeks in patients with advanced 
solid tumors.
Results
Patient characteristics and treatment. Figure  1 depicts the 3 + 3 dose-escalation study design; the 
Consort diagram is in Fig. 2. A total of 20 patients were enrolled in this phase I trial in five dose levels (DLs) 
(Table 1): 3 in DL1 and DL2, 4 in DL3 and DL5, and 6 in DL4. Since no dose-limiting toxicity was observed in 
DL1 and DL2, with olaparib administered from day 1 to 5, the study continued with the same 5-day schedule 
of oral olaparib from DL3 and beyond. The safety and efficacy analyses included all 20 patients. Most of the 
patients (75%) in the trial finished study treatment due to radiological progression, while 25% ended because 
of clinical progression (one patient in DL1 and one patient in DL5), toxicity (asthenia grade 3 in one patient in 
DL3 and hematological toxicity in one patient in DL5) and patient decision (one patient in DL3). Table 1 shows 
the patient characteristics for each cohort. All patients were female, and the most common type of tumour was 
ovarian cancer (n = 15; 75%). Median time from the primary tumour diagnosis and the inclusion in the trial 
was 33.9 (range 1.8–108.4) for DL5 and 80.3 months (range 10.9–127.1) for DL1. All patients included in this 
trial had previously been treated with systemic chemotherapy, with a median of 4–5 lines (range 1–7). Only one 
patient at DL1 had received 1 line and was platinum resistant.
Abbreviaons: DL, dose level; BID, twice daily
Olaparib intermittent dosing day 1-5/ 21-day treatment cycle
DL1: Lurbinectedin 1 mg/m2 + olaparib 100 mg BID
DL2: Lurbinectedin 1 mg/m2 + olaparib 150 mg BID
DL3: Lurbinectedin 1.5 mg/m2 + olaparib 200 mg BID
DL3: Lurbinectedin 1.5 mg/m2 + olaparib 250 mg BID
DL5: Lurbinectedin 2 mg/m2 + olaparib 250 mg BID
DL6: Lurbinectedin 2 mg/m2 + olaparib 300 mg BID
DL7: Lurbinectedin 3 mg/m2 + olaparib 300 mg BID
Study entry
If DL1 or DL2 were not 
tolerated, olaparib would be 
administered on days 1-3 of a 
21-day cycle.
Figure 1.  The 3 + 3 dose-escalation study design.
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Exposure to treatment. The median study treatment duration was from 27 days for DL2 to 127 days for 
DL3 (Table 1), while the maximum median number of cycles of olaparib and lurbinectedin was 6.5 for DL3. 
Patients from DL1 and DL2 received the fewest median number of cycles of lurbinectedin and olaparib.
The median cumulative dose of olaparib was higher at each subsequent cohort until DL3 (2000, 3000 and 
13,000 mg). Nevertheless, the median cumulative dose of olaparib in DL4 (13,500 mg) and DL5 (10,500 mg) was 
lower than in DL3 because of the more frequent dose reductions related to toxicity secondary to higher olaparib 
dose and the lower number of cycles administered in these DLs (median number of cycles were 6.5, 5 and 4.5 
for DL3, DL4 and DL5, respectively).
Regarding lurbinectedin, the highest cumulative dose of lurbinectedin was administered in patients in DL3 
because of the increased number of cycles administered and the lower rate of dose modifications. Most dose 
modifications (n = 3, 75%) occurred in the DL5 and were related to hematological toxicity.
Safety. All patients experienced ≥ 1 AE (Table 2). A total of 280 AEs were reported, being 167 events con-
sidered by the investigator related to study drugs. AEs (mostly grade 1–2) observed in ≥ 10% of all patients and 
by dose level are shown in Supplementary Table 1. Most common adverse events were: asthenia (55%), nausea 
(55%), vomiting (50%), constipation (45%), abdominal pain (40%), neutropenia (35%) and anemia (35%). Inci-
dence of grade 3–4 AEs was low and limited to DL3-DL5. Asthenia (15%) is the unique grade 3 non-hemato-
logical toxicity observed, whilst hematological toxicity was grade 3 anemia in two patients (10%) and grade 3 
and 4 neutropenia in 1 (5%) and two patients (10%), respectively. One patient at DL3 and another one at DL5 
discontinued the treatment because of AEs.
DLTs were observed in two patients who presented grade 4 neutropenia related to the combination of lurbi-
nectedin and olaparib in DL5. Therefore, DL4 was defined as the MTD, and the RP2D was lurbinectedin 1.5 mg/
m2 + olaparib 250 mg BID. No deaths related to the treatment occurred.
Pharmacokinetics. Pharmacokinetic data were available in 19 patients for lurbinectedin and olaparib. For 
the three lurbinectedin DLs explored, the mean lurbinectedin clearance (CL) was close to 12 L/h (Supplemen-
tary Fig. 1). Median lurbinectedin CL presented large variability (92%) at dose of 1 mg/m2 because one patient 
had high CL (37 L/h), while for the 1.5 mg/m2 and 2 mg/m2 DLs the variabilities were 36% and 52%, respectively 
(Supplementary Table 2). The stratification of lurbinectedin PK parameters by olaparib DL showed a large CL 






3 due to worsening of general condion
1 due to hyponatremia
1 due to anemia
1 due to bilirubin increased
1 due to infecon with fever
1 due to major surgery within 14 days 











1 paent was not evaluable for DLT because 
of poor compliance of olaparib dosing
2 paents presented DLT  
3 more paents were 
included in DL4  
Figure 2.  Consort diagram.
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variability when lurbinectedin was administered at 1 mg/m2 (olaparib 100 and 150 mg BID). In comparison, 
the next olaparib DLs (200 and 250 mg BID) matched with lurbinectedin DLs of 1.5 and 2 mg/m2, the CL vari-
abilities were close to 36% (Supplementary Fig. 2 and Table 3). At the highest olaparib DL (250 mg BID), mean 
lurbinectedin CL was 12 L/h which is the same to the mean CL as single-agent25 (Supplementary Fig. 2 and 
Table 3). We did not observe any potential drug–drug interactions (DDI) for lurbinectedin.
Regarding olaparib, PK parameters were calculated using noncompartmental analysis (NCA), and these did 
not show differences by lurbinectedin DL. When the parameters were stratified by olaparib DL, the CL at 100 mg 
was 3.0 L/h and higher (6–10 L/h) for the next DLs (Supplementary Fig. 3 and Table 3).
Efficacy. All 20 patients were evaluable for efficacy. The best global response was stable disease in 12 (60%) 
patients. By cohort, 66.67% in DL1, 75% in DL3, 66.67% in DL4 and 75% of patients in DL5 achieved stabiliza-
tion. None of the patients reached a complete or partial response in this trial.
Table 1.  Patient characteristics. BSA body surface area, DL dose level, ECOG PS Eastern Cooperative 












Age, median (range) (years) 62 (51–69) 60 (51–63) 62.5 (52–69) 56.5 (54–60) 61 (57–67)
ECOG PS, n (%)
0 2 (66.7) 2 (66.7) 1 (25) 5 (83.3) 2 (50)
1 1 (33.3) 1 (33.3) 3 (75) 1 (16.7) 2 (50)
BSA, median (range)  (m2) 1.59 (1.57–1.65) 1.9 (1.63–2.03) 1.78 (1.69–1.92) 1.78 (1.63–1.82) 1.59 (1.54–1.63)
Primary tumor type, n (%)
Ovarian cancer 3 (100) 3 (100) 2 (50) 5 (83.3) 2 (50)
High histological grade 3 (100) 2 (66.7) 2 (100) 5 (100) 1 (25)
Endometrium cancer – – 2 – 1 (25)
Uterine leiomyosarcoma – – – 1 (17.7)
Time from diagnosis to the inclusion, median (range) (months) 80.3 (11–127) 38.1 (26–61) 71.5 (58–99) 56.1 (39–61) 33.9 (16–72)
Lines of previous systemic therapy, median (range) 5 (1–6) 4 (4–6) 4 (2–6) 5 (3–6) 5 (3–7)
Previous radiotherapy, n (%) – – 2 (50) 1 (25)
Metastasis at baseline, n (%)
Lung – – 1 (25) 1 (16.7) 2 (50)
Liver 1 (33.3) 1 (33.3) 1 (25) 1 (16.7) 2 (50)
Lymph nodes 3 (100) 1 (33.3) 2 (50) 3 (50) 2 (50)
Bone – 1 (33.3) – – –
Others – 1 (33.3) 1 (25) 3 (50) 2 (50)
Treatment duration, median (range) (days) 45 (25–132) 27 (26–27) 127 (48–270) 87 (26–440 104 (59–180)
Number of cycles of olaparib, median (range) 2 (2–7) 2 (2–2) 6.5 (3–12) 5 (2–19) 4.5 (2–8)
Number of cycles of lurbinectedin, median (range) 3 (2–7) 2 (2–2) 6.5 (3–12) 5 (2–19) 4.5 (2–9)
Total cumulative dose of olaparib, median (range) (mg) 2000 (1700–6900) 3000 (3000–3000) 13,000 (5600–24,000) 12,500 (5000–15,000) 10,500 (6750–14,500)
Total cumulative dose of lurbinectedin, median (range) (mg) 5.1 (3.2–11.2) 3.9 (3.4–4) 17.5 (8.4–32.1) 12.4 (5.7–41.5) 12.3 (6.2–20)
Table 2.  Overview of safety. AE adverse event, DL dose level, DLT dose limiting toxicity.











Any AEs 3 (100) 3 (100) 3 (100) 6 (100) 4 (100)
Serious AE – – 1 (25) – 2 (50)
Grade 3–4 AE 3 (75) – 1 (25)
Treatment-related AE 3 (100) 2 (66.7) 4 (100) 4 (66.7) 4 (100)
Treatment-related serious AE – – – 1 (25)
Treatment-related Grade 3–4 AE 3 (100) 2 (66.7) 4 (100) 4 (66.7) 4 (100)
AE leading to treatment discontinuation 1 (25) 1 (25)
AE leading to olaparib dose delay or modification 2 (50) 1 (16.6) 2 (50)
AE leading to lurbinectedin dose delay or modification 2 (50) 1 (16.6) 2 (50)
AE leading to DLT – – – – 2 (50)
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An exploratory analysis of time to radiological progression (TTRP) was performed for the global population 
(Supplementary Fig. 4) and by DL (Supplementary Fig. 5). Median TTRP was 4.0 months (CI 95% 1.8–6.1) for 
the global population (Supplementary Fig. 4). TTRP could not be analyzed in patients from DL1 since two out 
of three patients were censored due to clinical progression. For the other DLs (2–5), TTRP was 1.8, 6.0, 3.6 and 
6.1 months, respectively (Supplementary Fig. 5).
Translational studies. Chemosensitivity to lurbinectedin and olaparib monotherapy and combined treat-
ment. Drug sensitivity was evaluated after fixing doses and time exposure to the drug. The dose–response 
curves were performed in the complete panel of ovarian cancer cell lines for lurbinectedin and olaparib. Except 
for OVCAR3, all cell lines presented a great sensitivity to lurbinectedin, showing an IC50 below 1 nM (Sup-
plementary Fig. 6). However, olaparib’s sensitivity range was found at a micromolar scale, thus facilitating the 
experimental and analytical procedures. In this case, cell lines showed higher differences in IC50, varying from 
2.9 to > 100 µM (Supplementary Fig. 7). IC50 comparison between HRD and no HRD cell lines showed a higher 
value in those not carrying mutation in this pathway, without statistical difference (Supplementary Fig. 8).
Administration of lurbinectedin and olaparib to TOV112 cell line was performed to corroborate if the drug 
combination was suitable for clinical application as already  described22. These experiments confirmed the pres-
ence of significant synergism, with a peak in the dose regions of 33–15% of cell survival (CI 0.1–0.17). The most 
synergistic doses were between 2 and 0.5 nM for lurbinectedin and IC50 nM for olaparib (Supplementary Fig. 9).
Western blot analysis. Protein levels of γH2AX and RAD51 were analyzed at four different time points 
(baseline and 4.5, 7 and 24 h after treatment administration) to determine when the changes in protein expres-
sion were statistically significant. Both proteins increased their concentration from baseline to 7 h, reaching 
the highest expression level and decreasing from this point forward. Only RAD51 suffered a significant protein 
increase (p = 0.007592) at 7 h (Fig. 3A). γH2AX levels show a trend in this sense (Fig. 3B).
Mutational analysis results: HR stratification. Material for mutational analysis was available for 13 
patients (11 ovarian cancer and 2 endometrial cancer patients). Among the 35 genes analyzed, 7 were found to 
be mutated: BRCA1, BRCA2, BRIP1, PTEN, RAD51B, SLX4 and TP53 (Fig. 4A). A total of 20 mutations were 
identified with 2 mutations/case (range 0–2). Only one sample of the series did not harbor any mutations.
TP53 alterations were found in 76.9% (10/13) of patients. However, only 2/13 (15.4%) presented PTEN 
mutation, matching with endometrial cancer patients. Samples were classified as HR proficient (do not harbor 
mutation in any HR gene) or HR deficient (BRCA1/2 or any HR gene mutated). A total of 7/13 (54%) patients 
presented mutations in HR pathway (Fig. 4B), five of them corresponding to BRCA1/2 genes. Histology, HRD 
status and response of each patient was displayed in Supplementary Table 4.
Discussion
The combination of lurbinectedin and olaparib showed a synergistic effect on cell lines that may be the reason 
for the increased efficacy and the toxicity observed in trials. With that in mind, we designed a dose-escalation 
study with different dose of lurbinectedin on day 1 and olaparib on days 1–5, but considering the possibility of 
reducing olaparib course to 3 days (days 1–3) as was amended to do in a previous  study13. However, olaparib 
reduction was not needed since no toxicity was observed in DL1 and DL2.
To our knowledge, this is the first study where the combination of lurbinectedin and a PARP inhibitor deemed 
feasible. In our trial, the combination of chemotherapy with olaparib’s dose schedule from day 1 to 5 was feasible. 
Previous combination trials using continuous olaparib had chemotherapy such as cisplatin and  gemcitabine26, 
cisplatin  alone13, and recently with carboplatin and/or  paclitaxel16 and  gemcitabine27 had an early stop due to 
high hematological toxicity. Only a continuous olaparib schedule and liposomal doxorubicin were successfully 
combined in a phase I  study28 and is currently being evaluated in a phase 2 trial (NCT03161132). Hence, only 
administration of low dose of continuous olaparib was tolerable. However, an intermittent dosage of olaparib, 
Figure 3.  (A) Boxplot comparing RAD51 protein level in peripheral blood mononuclear cell (PBMC) samples 
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especially short course, was feasible (Table 3). Combinations with intermittent olaparib capsules 200 mg BID 
on days 1–10 of every 21-day cycle with low dose carboplatin AUC of 4 and paclitaxel showed 43% grade 3 
 neutropenia14. Another report of intermittent olaparib and carboplatin plus paclitaxel failed to establish the MTD 
because more than half of the patients had dose modifications and delays due to  myelosuppression24. Although 
myelosuppression is a “class-toxicity” for all PARP inhibitors, other PARP inhibitors such as veliparib have been 
associated with lower myelosuppression in monotherapy studies and continuous administration of veliparib has 
been successfully combined with  chemotherapy29,30.
Our trial’s main non-hematological toxicities were nausea and asthenia, similar to what has been reported 
by van der Noll in the intermittent  trial24 and by Balmaña13. Neutropenia and anemia were observed in 15% 
and 10% of patients, respectively. The frequency of these hematological toxicities in our trial was lower than the 
reported  previously24. Overall, the combination of a short course of oral olaparib and lurbinectedin was well 
tolerated with manageable AEs. Based on the safety results, the recommended dose for the phase II study was 
lurbinectedin 1.5 mg/m2 on day 1 and olaparib capsules 250 mg BID on days 1–5 of a 21-day cycle.
In our trial, the pharmacokinetic analysis revealed no drug interactions for lurbinectedin or olaparib. The 
mean olaparib total body clearance of 7 L/h in our trial was comparable with the literature, with values of 5.1 L/h 
and 8.6 L/h31. However, the terminal half-life in our trial was shorter (3 h) than previously reported (between 
7 and 12 h), probably because these values were obtained from single-dose trials; while in this trial the NCA 
used samples until 6 h.
We did observe that both protein levels of RAD51 and H2AX increased consistently from baseline to 7 h. 
Regarding the limitations of the pharmacodynamic study of RAD51 and H2AX, we found pre-analytical and 
technical difficulties due to sample preservation and its use on western blot analysis. Massive contamination 
of erythrocytes in lymphocyte pellet (hemolyzed samples) made accurate colorimetric protein quantification 
Figure 4.  (A) Frequency of alterations across the studied DNA repair genes. (B) Main prognostic, histologic 
and molecular features of tumors included in the trial. *CO and CE correspond to histology type (Ovarian and 
endometrium, respectively).
Table 3.  Summary of main characteristics of combined phase I–II trials of olaparib and chemotherapy. AUC 
area under the curve, CBDCA carboplatin, CBR clinical benefit rate, CDDP cisplatin, Cont continuously, G3 
grade 3, int intermittently, iPARP poly (ADP-Ribose) polymerase inhibitor, OC ovarian cancer, Ola olaparib, 
PFS progression-free survival, PLD pegilated liposomal doxorubicin, PK pharmacokinetics, RR response rate, 
SD stable disease.
Study Chemotherapy iPARP dosage PK Toxicity Efficacy RR/PFS Comments
Oza (2015)14 CBDCA AUC4 Paclitaxel 175





PFS 12.2mo Feasible, toxic, only phase 2
Van der Noll (2019)24 CBDCA Paclitaxel Ola caps and tablet int Y Neutropenia 47% RR 46% Feasible,
Van der Noll (2019)16 CBDCA Paclitaxel Ola caps continuous Y Neutropenia 51%Thrombocytopenia 25% – Stopped
Rajan (2012)26 CDDP Gemcitabine Ola caps cont Y Neutropenia thrombocy-topenia – stopped
Balmaña (2014)13 CDDP Ola capsule cont Y Neutropenia 41%Nausea 78%
RR 41%
RR 43% OC and BRCA mut stopped
Lampert (2019)15 CBDCA Ola 1–7 Y Neutropenia 23% RR 20%CBR 64% feasible
Del Conte (2014)28 PLD Ola tablet cont/ int Y Stomatitis 73%Neutropenia 30% RR 33% Feasible
Bendell (2015)27 Gemcitabine Ola caps cont/int Y Hematological 55% – Feasible with very low doses
Present trial Lurbinectedin Ola tablet 1–5 Y
Asthenia 55%
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impossible. For this reason, results from a high number of samples were unsuitable, thus being excluded from 
data processing.
Oza et al.14 conducted a randomized phase II trial to assess olaparib capsules’ efficacy and tolerability plus 
carboplatin and paclitaxel versus carboplatin plus paclitaxel alone in patients with platinum-sensitive, recurrent, 
high-grade ovarian cancer. No differences in terms of response were observed between chemotherapy alone 
(58%) and the combination of chemotherapy plus olaparib (64%). On the other hand, the response rate of the 
study by van der Noll in a heavily pretreated, although highly selected ovarian cancer population, suggests a 
potential benefit of chemotherapy plus olaparib in a more advanced  disease24. In our study, the combination of 
lurbinectedin plus olaparib did not render any response in this population of heavily pretreated epithelial ovar-
ian and endometrial cancer without previous treatment with PARP inhibitors. However, the response rate was 
a secondary endpoint of the phase I trial and measurable disease was not required as an eligibility criterion. In 
the phase II trial we are going to assess the efficacy of the combination of olaparib and lurbinectedin in terms of 
response rate as the primary endpoint.
Homologous recombination deficiency (HRD) was found in the 54% of the analyzed samples, similar to 
previously reported  data32. Due to the short number of available samples, the lack of responses and the trial 
design (dose escalation); it is not possible to identify any population that might significantly benefit from the 
combination.
In summary, the combination of lurbinectedin and olaparib demonstrated a safe and tolerable profile. The 
RP2D was lurbinectedin 1.5 mg/m2 on day 1 and olaparib capsules 250 mg BID on days 1–5 of a 21-day cycle. The 
disease control rate that we obtained in this dose-escalation trial was stable disease (60%), but further evaluation 
in a phase II study in gynecological tumors regardless of BRCA status is needed. To the best of our knowledge, 
this is the first study of olaparib-based combination with acceptable AEs. As previously mentioned, our trial has 
several limitations, mainly the limited number and quality of the samples to perform the translational studies.
Material and methods
Study design and participants. This open-label, multicenter, phase Ib, dose-escalation trial enrolled 
patients with advanced solid tumors without established standard therapeutic alternatives. The primary objec-
tive was to evaluate safety and toxicity, identify the dose-limiting toxicity (DLT), estimate the maximum toler-
ated dose (MTD) and the recommended phase II dose (RP2D) of olaparib in combination with lurbinectedin. 
The secondary endpoints were overall response rate (ORR), the pharmacokinetics of the combination and addi-
tional translational research focused on the study of alterations in the DNA repair machinery by HR.
The study (NCT02684318, EudraCT 2015-001141-08, 03.10.2015) was approved by the ethics committee 
of the Hospital Vall d’Hebron and was conducted in accordance with the Declaration of Helsinki, ICH Good 
Clinical Practice guidelines and the current legislation. Written informed consent was obtained from all patients 
before study-specific procedures.
Patients histologically confirmed advanced or metastatic solid tumors were eligible if they were 18 years of 
age or older, and had an Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1. Other 
eligibility criteria included: no established effective therapy, adequate organ and bone marrow function, and 
ability to swallow oral medication.
Study treatment. Patients received lurbinectedin intravenously on day 1 at a starting dose of 1 mg/m2 
in combination with olaparib oral twice daily (BID) at an initial dose of 100 mg/12 h on days 1–5 of a cycle of 
21 days. Dose escalation following a standard 3 + 3 design. Patients were enrolled in successive dose-escalations 
dose levels (DL) for the combination according to Fig. 1. If DL1 or DL2 were not tolerated, then the same doses 
of both drugs were tested but administering olaparib on days 1–3 of each cycle of 21 days. Dose-limiting toxici-
ties (DLTs) were evaluated during cycle 1 and are in the “Supplementary Material”. MTD/RP2D was defined as 
the highest dose at which < 1 of 6 patients experience DLT during the first 21-day treatment period, with the next 
higher dose having at least two of the up to six patients undergoing a DLT during cycle 1. Intrapatient escalation 
was not allowed.
Study assessments. Hematology and biochemistry tests were performed at baseline, weekly during cycle 
1, and on day 1 and 15 during subsequent cycles. Electrocardiogram was done at baseline and repeated if clini-
cally indicated.
Tumor assessment was performed according to Response Evaluation Criteria in Solid Tumors version 1.1 
(RECIST v1.1) every other cycle until disease progression. ORR was defined as the proportion of patients with 
complete (CR) or partial response (PR). Time to radiological progression (TTRP) was defined as the time from 
inclusion until objective (RECIST v1.1) tumor progression. Adverse events (AE) and laboratory abnormali-
ties were graded with the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-
CTCAE) v.4.0.3 and coded using the Medical Dictionary for Regulatory Activities (MedDRA) v.14.1.
Blood samples for pharmacokinetic (PK) analyses were collected during cycle 1, with a schedule of ten sam-
ples (Supplementary Table 5).
Translational studies. Cell lines and culturing. The following Ovarian Cancer Cell lines were analyzed: 
TOV112, SKOV-3, OVCAR-3, PEO1, PEO6, PEO4, A2780 and A2780-Cis (an A2780 variant made resistant to 
platinum), representing the main different molecular subtypes of ovarian cancer (Supplementary Table 6). These 
cell lines were maintained at 37 °C in 5% CO2 in RPMI‐1640 medium (Sigma‐Aldrich Co.) and DMEM medium 
(Sigma‐Aldrich Co.), all supplemented with 10% heat‐inactivated FBS (Sigma‐Aldrich Co.). To verify the ge-
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netic profile of the cell lines, a characterization of microsatellite markers was carried out (AmpFlSTR Identifiler 
PCR Amplification Kit, AppliedBiosystem).
Cytotoxicity assay. For the pharmacological characterization of the different cell lines, dose–response curves 
were obtained for lurbinectedin (range between 25 and 0.0343 μM and 100–1.5625 μM dilution factor 3 and 2, 
respectively) and olaparib (range between 10 and 0.15625 nM). The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide) colorimetric assay measures the metabolic activity of viable cells, was used to deter-
mine the chemosensitivity of the cell lines. Cytotoxicity assay was assessed performing six technical replicates 
and three biological replicates per each curve point.
Before starting cytotoxicity assays to characterize the chemosensitivity of cell lines to study drugs, different 
time of exposures and doses were tested in order to establish the most suitable working conditions. Lurbinectedin 
was tested exposing the cells at three different time points, 1 h, 24 h and 72 h. In all cases, cell viability analysis 
was performed 72 h after treatment administration. Regarding olaparib, exposure times were established at 72, 
96 and 120 h, measuring absorbance directly after treatment exposure (Supplementary Fig. 10).
Based on the obtained results from the different tests performed with each drug and considering the subse-
quent administration of both drugs simultaneously, treatment conditions were fixed to 72 h of exposure followed 
by cell viability assay. Regarding lurbinectedin tests, cell viability results were comparable when exposing the cells 
during 24 and 72 h, while treating them during just 1 h was not enough to reach the IC50 value in the ranged 
concentrations. Due to olaparib’s molecular action inhibiting PARP, it was found that the higher time exposure, 
the lower IC50 values, changing proportionally. Hence, considering the concordance and suitability for applying 
72 h of exposure times to both drugs, this time point was selected as the treatment scheme.
For MTT assay, cells were plated and after 24 h of incubation, treated with the drug (lurbinectedin/olaparib) 
either as a single agent or with both agents simultaneously. MTT reagent was added to the samples 72 h after 
treatment administration at a concentration of 0.5 mg/mL and incubated during 4 h. After MTT removal, pro-
pranolol was added and mixed for 15 min. Finally, the absorbance was measured at 570 nm.
For combination treatments (lurbinectedin + olaparib), cells were treated with increasing doses of lurbinect-
edin and fixed doses of olaparib, using the calculated IC30 and IC50.
Generated data were analyzed using the Compusyn software (ComboSyn Inv.) and GraphPad Prism Software 
(GraphPad Inc.). We used the Chou–Talalay combination index (CI) method to quantify synergistic interactions 
between the drugs  tested33.
Blood collection and peripheral blood mononuclear cell isolation. Peripheral blood samples were collected at 
four different time points during the first cycle; before treatment administration and 4.5, 5.5 and 24 h after end-
ing lurbinectedin infusion. Additional sample at the end of treatment visit was also collected.
For Peripheral Blood Mononucleated Cell (PBMC) isolation, a total of 8 mL of peripheral blood were collected 
in EDTA tubes and separated in Histopaque (SIGMA) gradient by centrifugation. The solution was centrifuged 
at 290g for 20 min at 24 °C. Then PBMC layer was carefully collected using a Pasteur pipette, and cells were 
washed twice in PBS (5 min/1300 rpm/4 °C). Cells were resuspended in saline solution and centrifuged 90 s at 
13,000 rpm. Following this, supernatant was removed, and pelleted lymphocytes were stored at − 80 °C until 
their use for subsequent analyses.
Western blot analysis. PMBCs were lysed using 50–100 μL of lysis buffer (25 mM Tris–HCl pH 7.5, 1 mM 
EDTA pH 8,1 mM EDTA pH 8 and 1% SDS supplemented with protease and phosphatase inhibitors cocktail; 
leupeptine, pepstatine and Phenylmethylsulfonyl fluoride (PMSF)) depending on the characteristics of the sam-
ple. PMBCs were incubated 10 min at 95 °C, centrifuged at 16,000g for 10 min and maintained on ice. Once 
isolated, protein concentration was quantified by PierceTM BCA Protein assay Kit (ThermoFisher) following 
manufacturer’s protocol.
A total amount of 40 µg of protein per sample was separated on a 14% SDS-PAGE at 100 V and transferred 
into a nitrocellulose membrane during 3 h at 30 V (4 °C). Membranes were blocked for 1 h in 5% milk in Tris-
buffered saline (TBS)-Tween, and then, incubated with primary antibodies in 5% non-fat milk overnight at 4 °C. 
The following day, they were washed four times with TBS-T for a total of 30 min. Finally, secondary antibodies 
were incubated 1 h at room temperature and washed four times with TBS-T.
Membranes were revealed using ECL Prime Western Blotting System (Sigma Aldrich) according to the 
manufacturer’s instructions. To assess the presence of comparable amount of proteins in each lane (normalize 
the samples), membranes were stripped and incubated with β-actin (housekeeping protein).
Antibodies used were anti-RAD51 rabbit polyclonal antibody (PA5-27195, Thermofisher), dilution 1:1000, 
Anti-phospho-histone γH2AX mouse monoclonal antibody (Ser139, clone JLW301, MERCK) dilution 1:5000 
and Anti-β-Actine antibody (Anti-beta Actin antibody (ab8227), abcam) dilution 1:3000. Secondary antibodies 
against mouse (1:3000, Dako, Denmark) and rabbit (1:3000, Dako, Denmark) were used.
Genotyping. DNA extraction was performed using 3 × 20  μm-thin sections of formalin-fixed and paraffin-
embedded (FFPE) archived tumors and QIAmp DNA FFPE Tissue kit (Qiagen). The final concentration was 
measured spectrophotometrically using Nanodrop ND-1000 (Eppendorf). Additionally, concentration was 
determined fluorometrically with PicoGreen reagent using a quantifluor (Promega) instrument.
Libraries were prepared using the Agilent (Santa Clara, CA, USA) SureSelect-XT Target Enrichment Kit. 
Briefly, 200 ng of Extracted DNA was sheared on a Covaris M220 (Covaris) and fragmented to a size ranged 
between 150 and 200 bp. DNA integrity and fragment size were determined by a bioanalyzer, TapeStation 
4200 (Agilent). Each library was then hybridized to a SureSelect custom panel (Agilent) according to the 
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manufacturer’s protocol. The custom panel, designed to evaluate HRD status, included 35 genes involved in dif-
ferent DNA repair pathways; BRCA1, BRCA2, BARD1, BRIP1, CHEK1, CHEK2, FAM175A, NBN, PALB2, ATM, 
MRE11A, RAD51B, RAD51C, RAD51D, RAD54L, FANCI, FANCM, FANCA, ERCC1, ERCC2, ERCC6, REQL, 
XRCC4, HELQ, SLX4, WRN, ATR, PTEN, CCNE1, EMSY, TP53, MLH1, MSH2, MSH6 and PMS2. Pooled library 
was sequenced on a HiSeq2500 (Illumina, San Diego, CA, USA), using a 2 × 150-bp protocol. For annotation, 
the following categories were considered pathogenic, likely pathogenic or variants of uncertain significance 
(VUS) with pathogenic prediction or variants with both in silico predictors, SIFT and Polyphen, predicted as 
pathogenic. Variants were filtered based on coverage and functional annotation. Minimum coverage established 
for a variant was 100X. Median coverage in filtered variants was 656 reads (range 154–2158 reads). Mutations 
were accepted with a frequency higher than 5%.
Statistical analysis. Safety and efficacy population comprised all patients who received at least one dose of 
the study treatment. Continuous variables were presented with summary statistics and qualitative variables with 
the absolute and relative frequencies. In those cases where it was necessary to ensure the normality of the con-
tinuous parameters, log transformation (or other suitable transformation) was performed. Analysis of Variance 
(ANOVA) was used for exploratory group comparisons. If Gaussian distribution assumptions (Shapiro–Wilks 
test) were not met, equivalent nonparametric methods as the Kruskal–Wallis, were performed. Chi-squared 
or Fisher exact test were used for qualitative parameters. To explore the change in value of a variable, between 
baseline and week 12 or any other time point, a t-test for paired data or the Wilcoxon signed-rank test was per-
formed, based on the distribution followed by the corresponding variable. All statistical analyses were performed 
using IBM SPSS Statistics 22 and R v.3.4.3. PK analysis was performed according to the NCA. PK parameters 
were tabulated, and selected parameters were graphically displayed per DL for olaparib and lurbinectedin. The 
dose-exposure relationships for Cmax and AUC for lurbinectedin and AUC 0–6 for olaparib will be evaluated 
and any potential PK interaction between olaparib and lurbinectedin were also explored. The population phar-
macokinetics (PopPK) models for each drug was used to detect potential drug–drug interactions based on single 
agent PopPK models. The potential influence on selected PK parameters of selected demographic and clinical 
dichotomous variables (gender, laboratory test results above/below selected cutoff values, etc.) was evaluated by 
Student’s test Mann–Whitney’s U test as appropriate. For multinomial variables, analysis of variance was used. 
For selected continuous demographic and clinical variables, relationships with selected PK parameters were 
graphically explored and assessed using correlation and regression methods.
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